九芝堂表示，由于受外部环境、市场因素以及内部改革带来的短期调整等综合因素影响，公司部分产品 销售收入下降。 北京商报讯（记者 丁宁）8月21日，九芝堂（000989）披露2025年半年报显示，公司上半年实现营业收 入12.65亿元，同比下降24.71%；归属净利润1.44亿元，同比下降29.71%。 ...

格隆汇8月20日丨九芝堂(000989.SZ)公布2025年半年度报告，上半年公司实现营业收入12.65亿元，同比 下降24.71%；归属于上市公司股东的净利润1.44亿元，同比下降29.71%；归属于上市公司股东的扣除非 经常性损益的净利润1.36亿元，同比下降28.45%；基本每股收益0.1699元。 ...

Group 1 - The core viewpoint of the news is that Jiuzhitang Co., Ltd. has shown significant financial growth and advancements in its research and development projects during the first half of 2025, following a change in its controlling shareholder and leadership [1][2][3] - Jiuzhitang reported a revenue of 1.265 billion yuan and a net profit attributable to shareholders of 144 million yuan, with operating cash flow increasing by 191.72% compared to the same period last year [1] - The company has made progress in its organizational structure optimization, marketing reforms, and accelerated innovation in R&D, particularly in its stem cell projects and new drug candidates YB209 and YB211 [1][2] Group 2 - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed the development and validation of immunogenicity research methods and is nearing the end of Phase I clinical trials [1] - The YB211 project, a new cyclic lipopeptide antibiotic targeting drug-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled so far [1][2] - Jiuzhitang's subsidiary, Beijing Meike, has completed the enrollment of all 45 subjects in the Phase IIa clinical trial for stem cell treatment of ischemic stroke and has received approval for a clinical trial on autism treatment [2][3] Group 3 - Beijing Meike is exploring the application of stem cell therapy in more disease areas and has established a large-scale stem cell drug R&D production base compliant with GMP standards in China, the US, and the EU [3] - Jiuzhitang is actively investing in the development of new traditional Chinese medicine products and conducting real-world studies on existing key products, including the classic Chinese medicine formulas YB106 and YB107 [3] - The company aims to clarify the advantageous treatment areas of its key products through evidence-based research, supporting the upgrade of its traditional Chinese medicine varieties and fostering the development of major products [3]

Group 1 - The company achieved a revenue of 1.265 billion yuan and a net profit of 144 million yuan in the first half of 2025, with operating cash flow increasing by 191.72% compared to the same period last year [2] - The company is actively engaged in innovation and research, making significant progress in the fields of innovative drugs and stem cells [2] - The new major shareholder, Heilongjiang Provincial State-owned Assets Supervision and Administration Commission, took control of the company in January 2023, and a new chairman was appointed in July 2023 [2] Group 2 - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed method development and verification for immunogenicity research, with Phase I clinical trials nearing completion [2] - The YB211 project, targeting antibiotic-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled [2] - The company’s subsidiary, Beijing Meike, has completed enrollment for clinical trials on stem cell treatments for ischemic stroke and autoimmune pulmonary alveolar proteinosis [3] Group 3 - Beijing Meike has received approval for clinical trials using stem cells to treat autism, expanding the application prospects of its stem cell technology [3][4] - The company is also advancing the development of traditional Chinese medicine, with ongoing research on classic formulas and real-world studies for several key products [4] - The real-world study for the product Shuxuetong injection has registered 2,141 cases, and various other key products are undergoing clinical evidence-based research [4]

Core Viewpoint - Jiuzhitang (000989) is making significant progress in both traditional Chinese medicine and innovative drug development, particularly in stem cell therapy and new drug projects, as evidenced by its recent financial performance and ongoing clinical trials [1][2][3] Financial Performance - For the first half of 2025, Jiuzhitang reported a revenue of 1.265 billion yuan and a net profit attributable to shareholders of 144 million yuan, with operating cash flow increasing by 191.72% compared to the same period last year [1] Corporate Governance - In January 2025, the Heilongjiang Provincial State-owned Assets Supervision and Administration Commission became the new controlling shareholder of Jiuzhitang. In July, the company appointed Wang Lifeng as the new chairman and legal representative [1] Innovation and R&D Progress - Jiuzhitang is optimizing its organizational structure and accelerating marketing reforms while advancing its innovative research and development efforts, particularly in stem cell projects and drug candidates YB209 and YB211 [1] - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed method development and verification for immunogenicity studies, with Phase I clinical trials nearing completion [1] - The YB211 project, targeting antibiotic-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled, following the completion of clinical sample preparation and toxicity tests [1] Stem Cell Research - Jiuzhitang's subsidiary, Beijing Meike, has completed enrollment for 45 subjects in a Phase IIa clinical trial for ischemic stroke treatment using allogeneic bone marrow mesenchymal stem cells. Additionally, a clinical trial for treating autoimmune pulmonary alveolar proteinosis has enrolled 10 subjects [2] - Beijing Meike has received approval for a clinical trial using bone marrow mesenchymal stem cell injection for autism treatment, further expanding the application prospects of its stem cell technology [2] Commitment to Traditional Chinese Medicine - Jiuzhitang is actively engaged in the innovation and development of new traditional Chinese medicines, with ongoing research on classic formulas YB106 and YB107, and real-world studies for products like Shuxuetong injection [3] - The company is conducting clinical evidence-based research on several key products, which will clarify their therapeutic advantages and support the upgrade of its traditional Chinese medicine offerings [3]

每经AI快讯，九芝堂（SZ 000989，收盘价：11.83元）8月20日晚间发布公告称，公司第九届第九次董 事会会议于2025年8月19日在公司管理中心第一会议室以现场方式召开。会议审议了《九芝堂股份有限 公司2025年半年度报告》等文件。 2024年1至12月份，九芝堂的营业收入构成为：医药工业占比96.69%，医药商业占比2.95%，其他业务 占比0.36%。 截至发稿，九芝堂市值为101亿元。 每经头条（nbdtoutiao）——最火游资不再是方新侠、章盟主、佛山无影脚？这名95后声名鹊起！ （记者 王晓波） ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year, indicating potential challenges in its operational performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.265 billion yuan, representing a year-on-year decrease of 24.71% [2] - The net profit attributable to shareholders was around 144 million yuan, down 29.71% year-on-year [2] - Basic earnings per share were reported at 0.1699 yuan, reflecting a decrease of 29.18% compared to the same period last year [2]

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in the current market environment [1] Financial Performance - The company achieved an operating revenue of 1.265 billion yuan, representing a year-on-year decrease of 24.71% [1] - The net profit attributable to shareholders was 144 million yuan, down 29.71% compared to the previous year [1] - Basic earnings per share stood at 0.17 yuan [1] Factors Influencing Performance - The decline in sales revenue for some products was attributed to a combination of external environmental factors, market conditions, and short-term adjustments due to internal reforms [1]

九芝堂股份有限公司 2025 年半年度财务报告 九芝堂股份有限公司 2025 年半年度财务报告 2025-058 2025 年 8 月 21 日 1 九芝堂股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 297,134,857.34 | 592,879,984.54 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 560,000,000.00 | 300,000,000.00 | | 衍生金融资产 | | | | 应收票据 | 197,711,400.82 | 266,661,655.93 | | 应收账款 | 575,007,829.24 | 392,917,167.25 | | 应收款项融资 | 160,120,431.12 | 163,974,271.95 | | 预付款项 | 44,613,669.25 | 33,268,841.21 | | 应收保费 | | ...

| 细则早心:儿之里放订年限公司 | | | | | | | | | | 中:儿 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关联 | 算的会计科 | 上市公司核 复的会计科 | | 2025半年度占 用资金的利息 | 2025半年度偿还累计 2025年6月末占用 | | 占用形成原因 | 占用性质 | | | | 关系 | H | 金余额 | 金额(不含利息) | (如有) | 发生全额 | 登金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企 | | | | | | | | | | | | > | | | | | | | | | | | | 小计 | | | | | | | | | | | | 总计 | | | | | | | | | | | | 其他关联资金往来 | 资金往来方名称 | 往来方与上市公司的关 ...